The Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market:
https://www.thebusinessresearchcompany.com/report/acute-lymphocytic-lymphoblastic-leukemia-therapeutics-global-market-report
According to The Business Research Company’s Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Global Market Report 2024, The acute lymphocytic-lymphoblastic leukemia therapeutics market size has grown strongly in recent years. It will grow from $2.68 billion in 2023 to $2.85 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to chemotherapy advancements, biological and targeted therapies, pediatric oncology research, improved supportive care, stem cell transplantation.
The acute lymphocytic-lymphoblastic leukemia therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.51 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to personalized medicine approaches, expanded access to novel agents, global health initiatives, patient advocacy and awareness, regulatory pathway streamlining. Major trends in the forecast period include supportive care innovation, collaborative research efforts, diagnostic innovations, car-t cell therapies, innovations in biologics.
The growing prevalence of genetic conditions is expected to propel the growth of the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market going forward. Genetic conditions are medical conditions that are caused by changes (mutations) in an individual’s DNA or genes. Gene mutations can build up in cells in the body over time, and cells with too many mutations may stop working normally, grow out of control, and become cancerous. Genetic testing is used therapeutically to discover particular genetic anomalies in individuals with acute lymphocytic-lymphoblastic leukemia, which can assist in informing therapy choices. For instance, in June 2023, Gene People, a UK-based registered charity, The prevalence of genetic conditions in children is estimated to be 1 in 25. This indicates that over 2.4 million children and adults in the UK are affected by a genetic disorder. Additionally, it is estimated that 30,000 newborns and children receive new diagnoses of genetic conditions each year in the UK. Therefore, the growing prevalence of genetic conditions is driving the growth of the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13239&type=smp
The acute lymphocytic-lymphoblastic leukemia therapeutics market covered in this report is segmented –
1) Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market By Therapy Type: Chemotherapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplantation
2) Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market By Diagnosis: Biopsy And Bone Marrow Aspiration, Complete Blood Count (CBC) And Differential, Presence Of Philadelphia Chromosome, Spinal Tap And Cerebrospinal Fluid (CSF) Analysis, Immunophenotyping Or Phenotyping By Flow Cytometry, Polymerase Chain Reaction (PCR)
3) Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market By Cell Type: Philadelphia Chromosome, Precursor B-Cell Acute Lymphoblastic Leukemia (ALL), T-Cell Acute Lymphoblastic Leukemia (ALL)
4) Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market By Route Of Administration: Oral, Parenteral
5) Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market By Age Group: Pediatrics, Adults
Top Major Players
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
AbbVie Inc.
Novartis AG
Sanofi S.A.
Major companies operating in the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market are developing innovative therapies such as Tecartus (brexucabtagene autoleucel) by using chimeric antigen receptor (CAR) T-cell therapy and getting approvals to better meet the needs of their existing consumers. CAR T-cell therapy is a type of immunotherapy that uses a patient’s own T cells to fight cancer. For instance, in November 2021, Kite Pharma, a US-based biotechnology company received the approval for Tecartus from the Food and Drug Administration, a US-based federal agency adults with ALL. Tecartus is a CD19-directed genetically modified autologous T-cell immunotherapy, administered as a single infusion. Tecartus is the first and only CAR T-cell therapy approved for adults with ALL. The approval of Tecartus for the treatment of ALL has added value to Kite by expanding treatment options, increasing revenue potential, and demonstrating the company’s expertise in the field of cell therapy.
The acute lymphocytic-lymphoblastic leukemia therapeutics market report table of contents includes:
1. Executive Summary
2. Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Characteristics
3. Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Trends And Strategies
4. Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market – Macro Economic Scenario
5. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Size and Growth
…..
32. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Competitive Benchmarking
33. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market
35. Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Future Outlook and Potential Analysis
36. Appendix
Read Related Reports:
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
